Impact of conditioning regimen intensity on the outcomes of peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma patients undergoing allogeneic transplant
Abstract
There have been no large studies comparing reduced‐intensity/non‐myeloablative conditioning (RIC/NMA) to myeloablative conditioning (MAC) regimens in T‐cell non‐Hodgkin lymphoma (T‐NHL) patients undergoing allogeneic transplant (allo‐HCT). A total of 803 adults with peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma (age 18–65 years), undergoing allo‐HCT between 2008–2019 and reported to the Center for International Blood and Marrow Transplant Research with either MAC (n = 258) or RIC/NMA regimens (n = 545) were evaluated. There were no significant differences between the two cohorts in terms of patient sex, race and performance scores. Significantly more patients in the RIC/NMA cohort had peripheral blood grafts, haematopoietic cell transplantation‐specific comorbidity index (HCT‐CI) of ≥3 and chemosensitive disease compared to the MAC cohort. On multivariate analysis, overall survival (OS) was not significantly different in the RIC/NMA cohort compared to the MAC cohort (hazard ratio (HR) = 1.01, 95% confidence interval (CI) = 0.79–1.29; p = 0.95). Similarly, non‐relapse mortality (NRM) (HR = 0.85, 95% CI = 0.61–1.19; p = 0.34), risk of progression/relapse (HR = 1.29; 95% CI = 0.98–1.70; p = 0.07) and therapy failure (HR = 1.14; 95% CI = 0.92–1.41, p = 0.23) were not significantly different between the two cohorts. Relative to MAC, RIC/NMA was associated with a significantly lower risk of grade 3–4 acute graft‐versus‐host disease (HR = 0.67; 95% CI = 0.46–0.99, p = 0.04). Among chemorefractory patients, there was no difference in OS, therapy failure, relapse, or NRM between RIC/NMA and MAC regimens. In conclusion, we found no association between conditioning intensity and outcomes after allo‐HCT for T‐cell NHL.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 02, 2022
- Source ID
- 10.1111/bjh.18052
Entities
People
- Alex F. Herrera
- Amanda F. Cashen
- Andrew R. Rezvani
- Corey S. Cutler
- Craig S. Sauter
- Dipenkumar Modi
- Farhad Khimani
- Jasmine Zain
- Jonathan E. Brammer
- Kwang W. Ahn
- Malvi Savani
- Mazyar Shadman
- Mehdi Hamadani
- Mohamed A. Kharfan‐dabaja
- Sairah Ahmed
- Timothy S. Fenske
- Yue Chen
Organizations
- Angiocrine Bioscience (United States)
- Astellas Pharma (United States)
- Bristol-Myers Squibb
- Chiron Corporation
- City of Hope National Medical Center
- Daiichi Sankyo
- Dana–Farber Cancer Institute
- Genzyme
- H. Lee Moffitt Cancer Center & Research Institute
- Health Resources and Services Administration
- Incyte
- Janssen Pharmaceuticals
- Jazz Pharmaceuticals
- Johnson & Johnson
- Kiadis Pharma (Netherlands)
- Kirin Company
- Kite Pharma
- MSD (United Kingdom)
- Mayo Clinic
- Medical College of Wisconsin
- Miltenyi Biotec
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Marrow Donor Program
- Office of Naval Research
- Ohio State University
- Pharmacyclics
- Roche (United States)
- Stanford University
- StemCyte
- Takeda Pharmaceutical Company
- University of Arizona
- University of Texas at Austin
- University of Washington
- Washington University in St. Louis
- Wayne State University
- Weill Cornell Medicine
- bluebird bio